MYCN amplification and International Neuroblastoma Risk Group stratification on fine-needle aspiration biopsy and their correlation to survival in neuroblastoma

被引:3
作者
Bhardwaj, Neha [1 ]
Rohilla, Manish [2 ]
Trehan, Amita [3 ]
Bansal, Deepak [3 ]
Kakkar, Nandita [4 ]
Srinivasan, Radhika [2 ]
机构
[1] Post Grad Inst Med Educ & Res, Pathol, Chandigarh, India
[2] Post Grad Inst Med Educ & Res, Cytol & Gynecol Pathol, Chandigarh 160012, India
[3] Post Grad Inst Med Educ & Res, Dept Pediat Hematol Oncol Div, Chandigarh, India
[4] Post Grad Inst Med Educ & Res, Histopathol, Chandigarh, India
关键词
NEUROBLASTOMA; FISH; Pathology; Molecular; N-MYC; GENE AMPLIFICATION; NEURO-BLASTOMA; CYTOLOGY; CLASSIFICATION; DIAGNOSIS; CELL; ONCOGENE; CHILDREN; TUMOR;
D O I
10.1136/jclinpath-2022-208177
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims Risk stratification as per the International Neuroblastoma Risk Group (INRG) stratification is important for management of neuroblastoma. INRG incorporates various parameters including histological category as per the International Neuroblastoma Pathology Classification (INPC) and MYCN amplification, which were evaluated in fine needle aspiration biopsy (FNAB) samples of neuroblastoma patients to ascertain their impact in our population. Methods This was a retrospective study including 60 neuroblastoma cases diagnosed on FNAB, staged and stratified by INRG. Mitosis Karyorrhexis Index (MKI), INPC morphological category and MYCN status by fluorescence in situ hybridisation (n=46) were evaluated and correlated to outcome. Results The mean age was 29 months (21 days to 9 years) with 27 and 33 children </>= 18 months; male: female ratio of 1.6: 1; INRG stage-30(M), 20(L2), 2(L1) and 2(MS); INRG-36 high-risk, 13 intermediate-risk and 11 low-risk categories, respectively. MKI was high, intermediate and low in 39, 4 and 7 cases, respectively. INPC morphological type included 2 ganglioneuroblastomas and 58 neuroblastomas, graded further as 25 undifferentiated and 33 poorly differentiated tumours. MYCN was amplified in 48% (22/46) cases and correlated with undifferentiated morphology (p=0.01). At a mean follow-up of 469 (7-835) days, 22/50 were disease free and 28/50 had relapsed/died. The overall survival correlated with age (p=0.03), stage (p=0.01), INRG group (p=0.0001) and tumour grade (p=0.036). MYCN status independently did not correlate with age (p=0.5), INRG stage (p=0.2) and overall survival (p=0.4). Conclusion FNAB is a complete modality for diagnosing neuroblastoma and providing all information required for risk stratification as per INRG including MKI, MYCN amplification, INPC category. Our cohort with predominant high-risk neuroblastoma cases highlights regional variation.
引用
收藏
页码:599 / 605
页数:7
相关论文
共 39 条
  • [1] AKHTAR M, 1986, CANCER-AM CANCER SOC, V57, P797, DOI 10.1002/1097-0142(19860215)57:4<797::AID-CNCR2820570419>3.0.CO
  • [2] 2-A
  • [3] Quality assessment of genetic markers used for therapy stratification
    Ambros, IM
    Benard, J
    Boavida, M
    Bown, N
    Caron, H
    Combaret, V
    Couturier, J
    Darnfors, C
    Delattre, O
    Freeman-Edward, J
    Gambini, C
    Gross, N
    Hattinger, CM
    Luegmayr, A
    Lunec, J
    Martinsson, T
    Mazzocco, K
    Navarro, S
    Noguera, R
    O'Neill, S
    Pötschger, U
    Rumpler, S
    Speleman, F
    Tonini, GP
    Valent, A
    Van Roy, N
    Amann, G
    De Bernardi, B
    Kogner, P
    Ladenstein, R
    Mickon, J
    Pearson, ADJ
    Ambros, PF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) : 2077 - 2084
  • [4] Chromosome 1p and 11q deletions and outcome in neuroblastoma
    Attiyeh, EF
    London, WB
    Mossé, YP
    Wang, Q
    Winter, C
    Khazi, D
    McGrady, PW
    Seeger, RC
    Look, AT
    Shimada, H
    Brodeur, GM
    Cohn, SL
    Matthay, KK
    Maris, JM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21) : 2243 - 2253
  • [5] Genetic discoveries and treatment advances in neuroblastoma
    Bagatell, Rochelle
    Cohn, Susan L.
    [J]. CURRENT OPINION IN PEDIATRICS, 2016, 28 (01) : 19 - 25
  • [6] Bansal D, 2008, INDIAN PEDIATR, V45, P135
  • [7] Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
    Berbegall, Ana P.
    Bogen, Dominik
    Poetschger, Ulrike
    Beiske, Klaus
    Bown, Nick
    Combaret, Valerie
    Defferrari, Raffaella
    Jeison, Marta
    Mazzocco, Katia
    Varesio, Luigi
    Vicha, Ales
    Ash, Shifra
    Castel, Victoria
    Coze, Carole
    Ladenstein, Ruth
    Owens, Cormac
    Papadakis, Vassilios
    Ruud, Ellen
    Amann, Gabriele
    Sementa, Angela R.
    Navarro, Samuel
    Ambros, Peter F.
    Noguera, Rosa
    Ambros, Inge M.
    [J]. BRITISH JOURNAL OF CANCER, 2018, 118 (11) : 1502 - 1512
  • [8] Mitosis-Karyorrhexis Index evaluation by digital image visual analysis for application of International Neuroblastoma Pathology Classification in FNA biopsy
    Bhardwaj, Neha
    Rohilla, Manish
    Trehan, Amita
    Bansal, Deepak
    Kakkar, Nandita
    Srinivasan, Radhika
    [J]. CANCER CYTOPATHOLOGY, 2022, 130 (02) : 128 - 135
  • [9] Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations
    Bosse, Kristopher R.
    Maris, John M.
    [J]. CANCER, 2016, 122 (01) : 20 - 33
  • [10] Brodeur G, 2016, PRINCIPLES PRACTICE